Mark completed a BSc in Pharmaceutical and Chemical Science at Liverpool John Moores University in 2004 achieving the “Best Final Year Student” award sponsored by GlaxoSmithKline. He then completed a PhD (funded by ReProTect - a European Union research project) in the area of predictive toxicology in 2007. Mark went on to work as a post-doctoral researcher on two large research projects funded by the European Union and the Innovative Medicines Initiative. Work on both projects involved the development of computational tools for the toxicological assessment of pharmaceuticals with the aim of reducing the reliance on animal models. In 2014, Mark joined the University of Wolverhampton and is currently a senior lecturer in pharmaceutics involved in teaching on the MPharm, BSc Pharmaceutical Science, BSc Pharmacology, HND Pharmaceutical Science, Faculty of Science and Engineering Foundation Year and MSc degree courses within the School of Pharmacy.

Mark’s research interests include the application of predictive methods in drug discovery, design and development, computational drug screening and investigation of drug toxicity. Mark has been involved in the modelling of human hepatotoxicity, skin permeation, reproductive and developmental toxicities and the passage of drug across the placental barrier. Given the predictive nature of this research, Mark is also interested in model reliability (data quality assessment and definition of a models’ applicability domain) and the regulatory usage and acceptance of predictive methods to support drug development and the production of safer medicines.